Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Imbruvica

- PMLiVE

AbbVie preps uterine fibroid filing after phase 3 win

Second approval for Orilissa would boost blockbuster prospects

- PMLiVE

AbbVie sues NHS England over hep C procurement

Accuses NHS of not treating all bidders fairly

Roche Basel Switzerland

Roche and AbbVie prepare to move Venclexta into first-line CLL

Data shows an extended PFS compared to those on Gazyva plus chlorambucil chemo

- PMLiVE

Chinese biotech’s global ambitions

BeiGene aims to be the first home-grown big biopharma

- PMLiVE

Biopharma’s Future: Made in China

The world’s second biggest pharma market is entering a new growth phase – but meeting its needs takes investment and expertise

- PMLiVE

New data keeps AbbVie’s star pipeline therapies on track

Data showed 56% of patients on risankizumab were symptom free after a year’s treatment

- PMLiVE

AbbVie to develop argenx-partnered GARP-targeted immunotherapy

Will build on an initial $60m deal with the biotech

- PMLiVE

China’s BeiGene raises $903m from Hong Kong IPO

Mammoth debut might have exceeded $1bn but for market jitters

- PMLiVE

Daily Brief: Biosimilars ready to pounce on Humira, Hong Kong could rival Nasdaq, Kymab’s OX40 candidate

The latest from pharma, biotech and healthcare

- PMLiVE

AbbVie’s blockbuster-in-waiting for endometriosis gets FDA nod

First new oral treatment in more than 10 years

- PMLiVE

China’s BeiGene takes PD-1 antibody into pivotal trials

Firm aims to leapfrog immunotherapy leaders in huge market

Roche Basel Switzerland

Roche keeps Venclexta train rolling with new leukaemia filing

The drug could treat AML patients who are ineligible for chemotherapy

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links